ATS 2024 Final Program

Click on the session title to view the speakers

SUNDAY • MAY 19

101

2:56 Staying on the Right Path: Promoting Recovery and Preventing Re-Admission 3:08 Catching Patients Downstream: Starting Post-Sepsis Care Pre-Discharge 3:20 The Road to Recovery: Lessons Learned from Post-ICU Interventions 3:32 Panel Discussion and Questions

and a Q and A discussion about bridging research gaps to help inform future clinical practice. 2:15 Introduction: Lung Cancer Not Attributable to Smoking 2:18 Lung Cancer in Persons who Have Never Smoked: A Patient Perspective 2:23 Patterns of Vaping and Cannabis Product Use: New Products, New Challenges 2:36 What Did I Just Inhale? Vaping, Cannabis Use and the Risk of Cancer 2:49 Air Pollution and PM-2.5 as a Potential Environmental Lung Carcinogen 3:02 Secondhand Smoke and Other Inheritable and Non-Inheritable Risks 3:15 Deployment-Related Risks for Lung Cancer: Lessons Learned from Veteran Research 3:28 Q&A-Summing it up This session and the International Conference are supported by an independent medical educational grant from Merck&Co., Inc. All CMEsessions have been planned and implemented in accordancewith the AccreditationCriteria of theAccreditationCouncil for ContinuingMedical Education (ACCME ® ) and are free of the control of ineligible companies (formerly commercial interests). A88 POST-TB LUNG DISEASE: FROM GLOBAL BURDEN TO MOLECULAR MECHANISMS Assemblies on Pulmonary Infections and Tuberculosis; Allergy, Immunology and Inflammation 2:15 p.m. - 3:45 p.m. San Diego Convention Center Room 6C-F (Upper Level) Target Audience Researchers, clinicians, and public health practitioners who study or care for people with TB and post-TB chronic lung disease. Objectives At the conclusion of this session, the participant will be able to: • describe current understanding of the burden and clinical nature of post-TB lung disease • describe current understanding of molecular mechanisms of tissue damage after TB infection in model systems CLINICAL • TRANSLATIONAL SCIENTIFIC SYMPOSIUM

BASIC • BEHAVIORAL • CLINICAL SCIENTIFIC SYMPOSIUM

A87 IS IT IN THE AIR? EMERGING RISKS FOR LUNG CANCER Assemblies on Thoracic Oncology; Environmental, Occupational and Population Health; Tobacco Action Committee 2:15 p.m. - 3:45 p.m. Marriott Marquis San Diego Marina Pacific Ballroom 18-19 (Ground Floor, North Tower) Target Audience Clinicians with patients who vape or smoke cannabis or are at risk for lung cancer. Those with clinical, research, or administrative responsibilities related to lung cancer risk. Researchers interested in inhalational exposures. Objectives At the conclusion of this session, the participant will be able to: • identify established lung cancer risk factors beyond combustible tobacco • increase understanding of life-course implications of secondhand smoke exposure • describe mechanisms for how novel exposures increase carcinogenesis The proportion of lung cancers diagnosed in never tobacco users is nearing 20% and is expected to continue to rise, while tobacco use also does not account for all cancer risk in patients who have smoked. Emerging evidence supports a causal role of air pollution and other life-course exposures in lung cancer risk. New recreational products and the expanded legality of cannabis have implications for respiratory tract cancers in the future as more people habitually use these products. This session will discuss emerging evidence about risks for lung cancer other than personal combustible tobacco use. The session will feature a patient perspective related to nson-smoking related lung cancer

ATS 2024 Conference Program • San Diego, CA